As artificial intelligence becomes a powerful force in modern medicine, one question stands out — how can it be used responsibly in clinical practice? Join us for an engaging session, where global leaders will share their perspectives on integrating AI ethically, effectively, and safely into day-to-day medical decision-making. Speakers: Dr Amit Kum

Introduction CIDP is a chronic immune-mediated neuropathy characterized by progressive weakness, sensory loss, and functional disability. Standard treatments such as IVIg, corticosteroids, and plasma exchange may offer benefit but are associated with relapse, incomplete response, or treatment dependency. Riliprubart, a monoclonal antibody targeting

Introduction: Primary Progressive Multiple Sclerosis (PPMS) is characterised by a gradual accumulation of disability from disease onset, without relapses (1). This form of multiple sclerosis presents significant therapeutic challenges due to the absence of approved disease-modifying therapies (DMTs) (1). The pathophysiology of PPMS involves central

Background Multiple sclerosis (MS) is a chronic disease that affects the central nervous system and is characterized by inflammation, demyelination and degenerative changes (1). Approximately 85% of patients present with relapsing–remitting MS (RRMS), which is marked by recurrent relapses followed by partial recovery (1). Fingolimod (Gilenya) is th

Introduction Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated neuropathy characterized by motor and sensory dysfunction, often managed with IVIg, corticosteroids, or plasma exchange. Despite available treatments, relapse, incomplete response, and long-term dependency remain common challenges. Complement activity has be

Introduction Generalized Myasthenia Gravis (gMG) is a rare, chronic autoimmune neuromuscular disorder characterized by fluctuating skeletal muscle weakness and fatigue. The disease is primarily mediated by pathogenic autoantibodies targeting acetylcholine receptors (AChR) or muscle-specific kinase (MuSK) at the neuromuscular junction. These antibod

Introduction Schizophrenia is a chronic, debilitating psychiatric disorder affecting over 20 million people globally (1). Characterized by hallucinations, delusions, disorganized thinking, and negative symptoms such as apathy and social withdrawal, it imposes a significant burden on patients and healthcare systems (1,2). While antipsychotics remain

Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine.  Subcutaneous Therapy Enhances Early Heart Attack Intervention A Phase 3 trial has shown positive efficacy and safety results for a next-generation GPIIb/IIIa inhibitor designed for rapid, pre-hospital treatment of STEMI. Administered via

Introduction Generalized Myasthenia Gravis (gMG) is a chronic autoimmune neuromuscular disorder driven by pathogenic Immunoglobulin G (IgG) autoantibodies, most commonly targeting the acetylcholine receptor (AChR), muscle-specific tyrosine kinase (MuSK), or low-density lipoprotein receptor-related protein 4 (LRP4). These antibodies impair neuromusc